Extract
Bard to Sell Its Global Coronary Cath Lab Business to Arterial Vascular Engineering for $600 Million.
MURRAY HILL, N.J.--(BUSINESS WIRE)--July 9, 1998--C. R. Bard, Inc. (NYSE BCR) announced today that it has agreed to sell its global coronary cath lab business (angioplasty and angiography) to Ar...
See the full content of this document
Sponsored links
